March 2015

Oval Medical recently completed a £1.5m rights issue for the development of the manufacturing process for its novel autoinjector. The autoinjector facilitates the delivery of the new generation of biologics by eliminating issues including glass breakage, drug contamination and variable injection times.

This equipment will form part of the manufacturing process for clinical trial supplies for Oval’s sumatriptan autoinjector bioequivalence study and this manufacturing capability will be made available to Pharma customers for their own drug device combination products.